Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Gyre Therapeutics (GYRE) Cost of Revenue (2020 - 2026)

Gyre Therapeutics has reported Cost of Revenue over the past 6 years, most recently at $23.8 million for Q4 2025.

  • Quarterly Cost of Revenue rose 1923.45% to $23.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.5 million through Dec 2025, up 969.31% year-over-year, with the annual reading at $65.2 million for FY2025, 1578.14% up from the prior year.
  • Cost of Revenue was $23.8 million for Q4 2025 at Gyre Therapeutics, up from $1.6 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $57.8 million in Q4 2023 and troughed at $770000.0 in Q2 2024.
  • The 5-year median for Cost of Revenue is $1.3 million (2021), against an average of $7.3 million.
  • Year-over-year, Cost of Revenue soared 7109.38% in 2021 and then tumbled 97.96% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $2.5 million in 2021, then skyrocketed by 62.8% to $4.0 million in 2022, then skyrocketed by 1346.13% to $57.8 million in 2023, then tumbled by 97.96% to $1.2 million in 2024, then skyrocketed by 1923.45% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Cost of Revenue are $23.8 million (Q4 2025), $1.6 million (Q3 2025), and $15.2 million (Q2 2025).